ORIC

Over the past six months, ORIC's stock closed at $12.03 on October 8, 2026, with a 9.96% gain over three months, a 4.68% fall over the past month, and a 47.07% increase year-to-date. Analyst coverage includes Leerink Partners initiating an 'outperform' rating with a $26 price target in October 2026, BTIG Research initiating a 'Buy' rating with a $26 price target in September 2026, and H.C. Wainwright raising its target to $27; the consensus among 16 analysts is a 'Moderate Buy' with an average price target of $20.67. The CFO reportedly sold 13,400 shares near $13.53 on September 28, 2026. In March 2026, ORIC disclosed that a higher 600mg dose of rinzimetostat (ORIC-944) showed increased toxicity signals, leading to the selection of the 400mg dose for its planned global Phase 3 study, which has since been initiated; the company also anticipates 1L EGFR exon 20 monotherapy data and combination data for enozertinib in the second half of 2026. In August 2026, Oric reported a quarterly loss of $0.38 per share, slightly worse than the consensus estimate of $0.36. In August 2025, Oric Pharmaceuticals announced a 20% workforce reduction to focus resources on its two most advanced oncology drugs, ORIC-944 and enozertinib, and extend its cash runway.